Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cancer
    • Once weekly...

    Once weekly carfilzomib, promising for refractory myeloma patients

    Written by Medha Baranwal Baranwal Published On 2018-06-30T19:05:16+05:30  |  Updated On 30 Jun 2018 7:05 PM IST
    Once weekly carfilzomib, promising for refractory myeloma patients

    Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice-weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma, according to data from a study published in The Lancet Oncology.


    Philippe Moreau, Department of Hematology, University Hospital of Nantes, France, and colleagues conducted the phase III ARROW trial to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib.


    Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone.


    In the trial, 478 patients with R/R MM from 118 sites were randomized to receive once-weekly or twice-weekly carfilzomib in combination with dexamethasone in 28-day cycles until disease progression or unacceptable toxicity. The patients had previously received 2–3 treatments, including a proteasome inhibitor and an immunomodulatory agent.


    Patients in the once-weekly carfilzomib group received 30-minute intravenous infusion on days 1, 8 and 15 of all cycles (20 mg/m2 on day 1 in cycle 1, 70 mg/m2 thereafter). Those in the twice-weekly carfilzomib group received 10-minute intravenous infusion on days 1, 2, 8, 9, 15 and 16 (20 mg/m2 on days 1 and 2 in cycle 1, 27 mg/m2thereafter). Dexamethasone was given at a dosage of 40 mg on days 1, 8 and 15 in all cycles and on day 22 of cycles 1–9 only.


    Median carfilzomib exposure was 38 weeks in the once-weekly group and 29.1 weeks in the twice-weekly group, while median dexamethasone exposure was 37.1 weeks and 29.1 weeks, respectively.


    Key Findings:

    • In an interim analysis of the trial, patients randomized to receive once-weekly carfilzomib (70 mg/m2) plus dexamethasone showed a significant 31 percent improvement in progression-free survival (PFS) vs those who received twice-weekly carfilzomib (27 mg/m2) plus dexamethasone (median, 11.2 months vs 7.6 months; hazard ratio [HR], 0.69; p=0.0029).

    • In addition to improvement in the primary endpoint of PFS, patients on once-weekly carfilzomib also had a significantly higher overall response rate [ORR] vs those on the currently approved twice-weekly dosing regimen (62.9 percent vs 40.8 percent).

    • Complete response or better was achieved by 7 percent of patients on once-weekly carfilzomib vs 2 percent of those on twice-weekly carfilzomib, while very good partial response or better was achieved by 34 percent vs 13 percent of the patients.

    • Compared with the twice-weekly dosing schedule, once-weekly carfilzomib showed a favorable benefit-risk profile and is more convenient.

    • Grade ≥3 adverse events occurred in 68 percent of patients on once-weekly carfilzomib vs 62 percent of patients on twice-weekly dosing.

    • Frequent grade ≥3 adverse events included anemia (18 percent in both groups), pneumonia (10 percent vs 7 percent), thrombocytopenia (7 percent in both groups), neutropenia (6 percent vs 7 percent), and decreased platelet count (4 percent vs 5 percent).


    "Once weekly carfilzomib at 70 mg/m2 significantly prolonged progression-free survival versus the twice-weekly schedule. Overall safety was comparable between the groups. Once weekly carfilzomib appears safe and more effective with a convenient dosing regimen versus the twice-weekly schedule for the treatment of patients with relapsed and refractory multiple myeloma," concluded the authors.


    For further reference log on to https://doi.org/10.1016/S1470-2045(18)30354-1

    carfilzomibdexamethasonedosingmultiple myelomamyelomaneutropeniaPhilippe Moreauplatelet countpneumoniaprogression free survivalrefractory multiple myelomarelapsed multiple myelomaThe Lancet Oncologythrombocytopenia
    Source : With inputs from The Lancet Oncology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok